| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/MOT.0B013E32833DA439 |
| P953 | full work available at URL | https://journals.lww.com/10.1097/MOT.0b013e32833da439 |
| P698 | PubMed publication ID | 20733490 |
| P50 | author | John Bucuvalas | Q87612565 |
| P2093 | author name string | Kathleen M. Campbell | |
| P2860 | cites work | Chronic renal failure after transplantation of a nonrenal organ | Q28204928 |
| Mechanisms of nephrotoxicity | Q33980072 | ||
| Hypertension and renal dysfunction in long-term liver transplant recipients | Q34426372 | ||
| Renal impairment after liver transplantation - a pilot trial of calcineurin inhibitor-free vs. calcineurin inhibitor sparing immunosuppression in patients with mildly impaired renal function after liver transplantation | Q35959103 | ||
| High prevalence of renal dysfunction in long-term survivors after pediatric liver transplantation. | Q36463557 | ||
| Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease | Q37259666 | ||
| Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. | Q37397805 | ||
| Renal biopsy in liver transplant recipients | Q37416844 | ||
| Long-term management of the liver transplant patient: recommendations for the primary care doctor. | Q37534775 | ||
| Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study) | Q38904893 | ||
| Renal insufficiency after heart transplantation: a case-control study | Q40840919 | ||
| Improvement of renal function after conversion to mycophenolate mofetil combined with low-level calcineurin inhibitor in liver transplant recipients with chronic renal dysfunction | Q42469032 | ||
| Monitoring cyclosporine microemulsion at two hours post dosing in pediatric maintenance liver transplant recipients | Q43155454 | ||
| Renoprotective effects of telmisartan in patients with advanced chronic kidney disease. | Q43175298 | ||
| The variable pathology of kidney disease after liver transplantation | Q43185129 | ||
| Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction | Q43235824 | ||
| Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study | Q43283437 | ||
| Combined mycophenolate mofetil and minimal dose calcineurin inhibitor therapy in liver transplant patients: clinical results of a prospective randomized study | Q43283959 | ||
| ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation | Q43566691 | ||
| The impairment of true glomerular filtration rate in long-term cyclosporine-treated pediatric allograft recipients | Q43601411 | ||
| Renal function before and long after liver transplantation in children | Q43729197 | ||
| Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study | Q43815696 | ||
| End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment | Q43843805 | ||
| Chronic renal dysfunction late after liver transplantation | Q44165114 | ||
| Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement | Q44255121 | ||
| Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients | Q44486217 | ||
| Independent risk factors and natural history of renal dysfunction in liver transplant recipients | Q44492183 | ||
| The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation | Q44818440 | ||
| Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients. | Q46125058 | ||
| Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. | Q46177061 | ||
| Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study. | Q46220650 | ||
| Normal glomerular filtration rate in long-term follow-up of children after orthotopic liver transplantation | Q46988859 | ||
| Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. | Q53913637 | ||
| Serial decrease in glomerular filtration rate in long-term pediatric liver transplantation survivors treated with cyclosporine | Q69486615 | ||
| Renal function and histopathologic changes in children after liver transplantation | Q72896888 | ||
| Systemic hypertension and renal function in long-term liver transplant recipients on cyclosporine | Q73544667 | ||
| The MDR1/ABCB1 gene, a high-impact risk factor for cardiac transplant rejection | Q79468600 | ||
| Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients | Q80102169 | ||
| Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements | Q80252228 | ||
| Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients | Q83182880 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biopsy | Q179991 |
| liver transplantation | Q1368191 | ||
| P304 | page(s) | 608-613 | |
| P577 | publication date | 2010-10-01 | |
| P1433 | published in | Current opinion in organ transplantation | Q26842426 |
| P1476 | title | Renal function in the long term after pediatric liver transplantation: is there a need for protocol kidney biopsies? | |
| P478 | volume | 15 |
| Q38530791 | Current developments in pediatric liver transplantation |
| Q40132359 | Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: Results from a multicenter, prospective study. |
| Q96639297 | Safety and Efficacy of Everolimus Rescue Treatment After Pediatric Living Donor Liver Transplantation |
| Q38248591 | The role of everolimus in liver transplantation |
Search more.